Advanced search
Publication Cover
Leukemia & Lymphoma Volume 49, 2008 - Issue 9
Submit an article Journal homepage
212
Views
14
CrossRef citations to date
0
Altmetric
Reviews

GM-CSF plus rituximab immunotherapy: Translation of biologic mechanisms into therapy for indolent B-cell lymphomas

Stephen J. Schuster Hematology-Oncology Division, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA
,
Parameswaran Venugopal Rush University Medical Center, Chicago, IL, USA
,
Julie C. Kern MHCC, West Conshohocken, PA, USA
&
Peter McLaughlin University of Texas M.D. Anderson Cancer Center, Department of Lymphoma/Myeloma, Houston, TX, USACorrespondence[email protected]
Pages 1681-1692 | Received 07 Apr 2008, Accepted 20 May 2008, Published online: 01 Jul 2009

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Paolo Strati, Wei-Gang Tong, Candida Vitale, William G. Wierda, Susan O’Brien, Jennifer R. Brown, Wen-Kai Weng, Thomas Kipps, Michael J. Keating & Alessandra Ferrajoli. (2015) A phase II study of the combination of rituximab and granulocyte macrophage colony stimulating factor as treatment of patients with chronic lymphocytic leukemia. Leukemia & Lymphoma 56:6, pages 1878-1880.
Read now
Reem Karmali, Melissa L. Larson, James E. Wooldridge, Stephanie A. Gregory, Teresa O'Brien, Jamile M. Shammo, Katherine Bueschel & Parameswaran Venugopal. (2011) Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma. Leukemia & Lymphoma 52:11, pages 2097-2104.
Read now
Chadi Nabhan, Neil Dalal, Jayesh Mehta & Neil E. Kay. (2011) Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapies. Leukemia & Lymphoma 52:3, pages 374-386.
Read now
Claudia Stolz & Martin Schuler. (2009) Molecular mechanisms of resistance to Rituximab and pharmacologic strategies for its circumvention. Leukemia & Lymphoma 50:6, pages 873-885.
Read now

Articles from other publishers (10)

Shunrong Sun, Wulipan Fulati, Lin Shen, Min Wu, Zilan Huang, Wensi Qian, Pingping Chen, Yingwei Hu, Mingyue Chen, Yu Xu, Hongdi Zhang, Jiexian Ma & Yanhui Xie. (2023) Maintenance regimen of GM‐CSF with rituximab and lenalidomide improves survival in high‐risk B‐cell lymphoma by modulating natural killer cells . Cancer Medicine 12:12, pages 12975-12985.
Crossref
Vasiliki Lagou, Josselyn E. Garcia-Perez, Ide Smets, Lies Van Horebeek, Marijne Vandebergh, Liye Chen, Klara Mallants, Teresa Prezzemolo, Kelly Hilven, Stephanie Humblet-Baron, Matthieu Moisse, Philip Van Damme, Guy Boeckxstaens, Paul Bowness, Bénédicte Dubois, James Dooley, Adrian Liston & An Goris. (2018) Genetic Architecture of Adaptive Immune System Identifies Key Immune Regulators. Cell Reports 25:3, pages 798-810.e6.
Crossref
Jonathon B. Cohen, Silvana Bucur, Elliott F. Winton, Rajni Sinha, Leonard T. Heffner, Nassoma King, Sagar Lonial, Amelia A. Langston, Edmund K. Waller, Amanda Hutchison-Rzepka, Amanda Colbert, Mary Jo Lechowicz & Christopher R. Flowers. (2015) Combination of GM-CSF With Fludarabine-Containing Regimens in Chronic Lymphocytic Leukemia and Indolent Non-Hodgkin Lymphoma. Clinical Lymphoma Myeloma and Leukemia 15:9, pages 514-518.
Crossref
Xiaoyi Liu, Jianxia Hu, Weihong Cao, Huili Qu, Yu Wang, Zhongliang Ma & Funian Li. (2013) Effects of two different immunotherapies on triple negative breast cancer in animal model. Cellular Immunology 284:1-2, pages 111-118.
Crossref
Michael J. Corbley. 2012. Signaling Pathways in Cancer Pathogenesis and Therapy. Signaling Pathways in Cancer Pathogenesis and Therapy 109 144 .
S. Lanfranconi, F. Locatelli, S. Corti, L. Candelise, G. P. Comi, P. L. Baron, S. Strazzer, N. Bresolin & A. Bersano. (2011) Growth factors in ischemic stroke. Journal of Cellular and Molecular Medicine 15:8, pages 1645-1687.
Crossref
William K. Decker & Amar Safdar. (2011) Cytokine adjuvants for vaccine therapy of neoplastic and infectious disease. Cytokine & Growth Factor Reviews 22:4, pages 177-187.
Crossref
Shun’ichiro Taniguchi, Minoru Fujimori, Takayuki Sasaki, Hiroko Tsutsui, Yuko Shimatani, Keiichi Seki & Jun Amano. (2010) Targeting solid tumors with non-pathogenic obligate anaerobic bacteria. Cancer Science 101:9, pages 1925-1932.
Crossref
Deborah A. Thomas, Susan O'Brien & Hagop M. Kantarjian. (2009) Monoclonal Antibody Therapy with Rituximab for Acute Lymphoblastic Leukemia. Hematology/Oncology Clinics of North America 23:5, pages 949-971.
Crossref
William K. Decker & Amar Safdar. (2009) Bioimmunoadjuvants for the treatment of neoplastic and infectious disease: Coley's legacy revisited. Cytokine & Growth Factor Reviews 20:4, pages 271-281.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.